Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 sham-controlled nusinersen study in spinal muscular atrophy patients ineligible for CS3B or CS4
2014-003657-33Phase 2Completed
- Sponsor
- Biogen
- Start
- May 2015
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nusinersen in spinal muscular atrophy (SMA) (2 arms), sponsored by Biogen. Primary endpoint: Number of participants with adverse events and serious adverse events. Started May 2015; status: completed.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on 2014-003657-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003657-33.